Related Experiment Video
Updated: Jun 7, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms.
David M Dorfman1, Aliakbar Shahsafaei
1Dept of Pathology, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA. ddorfman@partners.org
American Journal of Clinical Pathology
|October 21, 2010
Summary
CD200, a protein, is found in various B-cell cancers, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This finding suggests CD200 may aid in diagnosing B-cell neoplasms and identify new therapeutic targets.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- CD200 is a membrane glycoprotein belonging to the immunoglobulin superfamily.
- Its expression patterns in various B-cell malignancies require further elucidation.
Purpose of the Study:
- To investigate the expression of CD200 in a broad spectrum of B-cell-derived neoplasms.
- To assess the potential utility of CD200 as an immunophenotypic marker and therapeutic target in these diseases.
Main Methods:
- Immunohistochemical staining was performed on paraffin-embedded tissue sections.
- The study analyzed a wide range of B-cell neoplasms.
Main Results:
- CD200 expression was detected in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Additional B-cell lymphoproliferative disorders, including hairy cell leukemia and classical Hodgkin lymphoma, showed CD200 immunoreactivity.
- Neoplastic cells in B-lymphoblastic leukemia/lymphoma also expressed CD200.
Conclusions:
- CD200 may serve as a valuable immunophenotypic marker for evaluating B-cell-derived neoplasms.
- The expression of CD200 in various B-cell malignancies suggests potential therapeutic applications for anti-CD200 immunotherapeutic agents currently in clinical trials.
Related Concept Videos
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:18Lymphoid Cells and Tissues
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...